Novo’s weight loss pill attracts rival’s customers
A Truveta study shows that nearly 16 percent of patients prescribed Novo Nordisk’s new weight-loss pill previously used Eli Lilly’s injectable drug, Zepbound. The study analyzed 8,762 patients in the six weeks following its US approval. As the first oral GLP-1 treatment for obesity, the semaglutide-based pill provides an alternative for patients who avoid injections. […]